Could beta-Myrcene (cas 123-35-3) be an alternative to albendazole for the treatment of experimental cystic echinococcosis?

Add time:09/08/2019    Source:sciencedirect.com

Echinococcus granulosus causes hydatidosis or cystic echinococcosis in humans and livestock. In humans, this disease can be managed with surgery, percutaneous treatment, chemotherapy and/or observation. The chemotherapeutic agents used and approved for treatment of hydatidosis are benzimidazoles. Because of the difficulties in achieving successful treatment, considerable efforts have been made to find new natural compounds against hydatid disease. Beta-myrcene is a monoterpene presented in the essential oils of different plants. It is the principal component of essential oil of Rosmarinus officinalis (rosemary). The goal of the present study was to evaluate the in vitro effects of beta-myrcene against germinal cells, protoscoleces and murine cyst of E. granulosus, as well also, investigate its chemoprophylactic activity in a murine model of cystic echinococcosis. For the in vitro assays, the parasites were incubated with beta-myrcene at 10, 5 and 1 μg/mL. The treatments were dose and time-dependent, and consistent with the observed morphological alterations. In the chemoprophylactic efficacy study, the effect of beta-myrcene was similar to albendazole, the reference drug for human echinococcosis treatment.

We also recommend Trading Suppliers and Manufacturers of Myrcene (cas 123-35-3). Pls Click Website Link as below: cas 123-35-3 suppliers

Prev:Green approach toward sustainable adhesive: Synthesis and characterization of poly(Myrcene (cas 123-35-3) sulfone)
Next:Absence of renal adverse effects from β-Myrcene (cas 123-35-3) dietary administration in OECD guideline-compliant subchronic toxicity study)